Astrazeneca (AZN) Intangibles (2016 - 2026)

Astrazeneca has reported Intangibles over the past 18 years, most recently at $36.9 billion for Q1 2026.

For Q1 2026, Intangibles fell 1.71% year-over-year to $36.9 billion; the TTM value through Mar 2026 reached $36.9 billion, down 1.71%, while the annual FY2025 figure was $37.8 billion, 1.8% up from the prior year.
Intangibles for Q1 2026 was $36.9 billion at Astrazeneca, down from $37.8 billion in the prior quarter.
Over five years, Intangibles peaked at $41.3 billion in Q1 2022 and troughed at $2.7 billion in Q4 2023.
A 5-year average of $36.5 billion and a median of $38.3 billion in 2023 define the central range for Intangibles.
Biggest five-year swings in Intangibles: crashed 93.11% in 2023 and later skyrocketed 1273.37% in 2024.
Year by year, Intangibles stood at $39.3 billion in 2022, then crashed by 93.11% to $2.7 billion in 2023, then skyrocketed by 1273.37% to $37.2 billion in 2024, then rose by 1.8% to $37.8 billion in 2025, then fell by 2.48% to $36.9 billion in 2026.
Business Quant data shows Intangibles for AZN at $36.9 billion in Q1 2026, $37.8 billion in Q4 2025, and $38.2 billion in Q3 2025.

Peer Comparison